CN105687189A - Medicine composition for treating upper respiratory tract infection - Google Patents
Medicine composition for treating upper respiratory tract infection Download PDFInfo
- Publication number
- CN105687189A CN105687189A CN201610130125.5A CN201610130125A CN105687189A CN 105687189 A CN105687189 A CN 105687189A CN 201610130125 A CN201610130125 A CN 201610130125A CN 105687189 A CN105687189 A CN 105687189A
- Authority
- CN
- China
- Prior art keywords
- compound
- respiratory tract
- upper respiratory
- tract infection
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC1=*(C[n](c(*NO)c2)nc2*2=C*=CC*C2)CCC*([N+]([O-])=O)=C1 Chemical compound CC1=*(C[n](c(*NO)c2)nc2*2=C*=CC*C2)CCC*([N+]([O-])=O)=C1 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to medicine composition for treating upper respiratory tract infection. The medicine composition comprises a compound in an effective quantity and a pharmaceutically acceptable carrier, wherein the compound has the structure shown in the specification. The compound has a remarkable resistant effect on pathogenic bacteria causing upper respiratory tract infection and can be developed into the novel medicine composition effective in clinic.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition treating upper respiratory tract infection。
Background technology
Upper respiratory tract infection is called for short upper sense, also known as common cold。It it is the general name including nasal cavity, pharynx or acute throat inflammation。The upper sense of broad sense is not a medical diagnosis on disease, but one group of disease, including common cold, viral pharyngitis, laryngitis, herpangina, pharyngoconjunctival fever, bacterial pharyngotonsillitis。The upper sense of narrow sense, also known as common cold, is modal acute infections of respiratory tract disease, and how in self limiting, but incidence rate is higher。Adult is annual to be occurred 2～4 times, and child's incidence rate is higher, annual 6～8 times。The whole year all can fall ill, and winter-spring season is more。In the patient illness part secretions of upper respiratory tract infection, find that legionella pneumophilia ATCC33152 is also one of pathogenic bacterium therein in the recent period。
Summary of the invention
It is an object of the invention to provide a kind of pharmaceutical composition treating upper respiratory tract infection。
In order to realize the purpose of the present invention, the present invention provides a kind of compound treating upper respiratory tract infection, and this compound has having structure:
The present invention also provides for a kind of pharmaceutical composition treating upper respiratory tract infection, and described pharmaceutical composition comprises the compound of effective dose and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizer or corrigent。
Preferably, described diluent is sugar derivatives, starch derivatives or cellulose derivative。
Preferably, described diluent is lactose。
Preferably, described pharmaceutical composition is powder, microgranule, granule, capsule or tablet。
The present invention also provides for compound purposes in the medicine of preparation treatment upper respiratory tract infection, and this compound has having structure:
Preferably, described infection is caused by legionella pneumophilia ATCC33152。
The present invention also provides for compound purposes in the medicine of preparation vitro inhibition legionella pneumophilia ATCC33152, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to the material of biologic activity or the character not eliminating compound as herein described, such as carrier or diluent。This kind of material is applied to individuality and is not resulted in undesirable biological action or not with harmful way and any component interaction in the compositions comprising it。
" pharmaceutically acceptable carrier " includes any and all of solvent as the term is employed herein, disperse medium, coating material, surfactant, antioxidant, preservative (such as antibacterial, antifungal), isotonic agent, absorption delay agent, salt, preservative, drug stabilizing agent, binding agent, excipient, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329)。Except with the inconsistent carrier of active component, consider to use any conventional carrier in treatment or pharmaceutical composition。
The compound of the present invention is notable for the pathogen effect causing upper respiratory tract infection, it is possible to develop into pharmaceutical composition effectively new clinically。
Detailed description of the invention
Below by way of the description of detailed description of the invention, the invention will be further described, but this is not limitation of the present invention, those skilled in the art's basic thought according to the present invention, various modifications may be made or improves, but without departing from the basic thought of the present invention, all within the scope of the present invention。
The research of experimental example the compounds of this invention purposes in the medicine of preparation vitro inhibition legionella pneumophilia ATCC33152
Bacteriostatic test
Use following compounds, adopt filter paper enzyme classical in this area to carry out bacteriostatic test, wherein:
The structural formula of target compound is:
For examination strain legionella pneumophilia ATCC33152 purchased from Fu Xiang bio tech ltd, Shanghai。
Culture fluid
Nutrient agar and nutrient broth, purchased from Chen Yu experimental facilities company limited of BeiJing ZhongKe。
Test method
Legionella pneumophilia ATCC33152 is inoculated in agar plate nutritional solution plane, uniformly gathers during inoculation。
Weighing target compound 0.01 gram, add 25000 ml sterile waters, ultrasonic 30 minutes, then the filtering with microporous membrane of 0.22 μm, obtained solution。The aseptic circular filter paper sheet of tweezer, sprays above-mentioned solution to complete wetting, is attached in the agar plate nutritional solution plane of inoculated bacteria。Agar plate is placed in the incubator of 37 DEG C, incubation 4 hours。Measure the diameter of antibacterial ring。Measure and average for 3 times。
1.4 results
The average diameter of the antibacterial ring of legionella pneumophilia ATCC33152 is 14.66mm, and this shows that target compound has the effect of extremely strong vitro inhibition legionella pneumophilia ATCC33152。
Claims (9)
1. the compound treating upper respiratory tract infection, it is characterised in that this compound has having structure:
2. the pharmaceutical composition treating upper respiratory tract infection, it is characterised in that described pharmaceutical composition comprises the compound of effective dose and pharmaceutically acceptable carrier, and described compound has having structure:
3. the pharmaceutical composition for the treatment of upper respiratory tract infection according to claim 2, it is characterised in that described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizer or corrigent。
4. the pharmaceutical composition for the treatment of upper respiratory tract infection according to claim 3, it is characterised in that described diluent is sugar derivatives, starch derivatives or cellulose derivative。
5. the pharmaceutical composition for the treatment of upper respiratory tract infection according to claim 4, it is characterised in that described diluent is lactose。
6. the pharmaceutical composition for the treatment of upper respiratory tract infection according to claim 3, it is characterised in that described pharmaceutical composition is powder, microgranule, granule, capsule or tablet。
7. compound purposes in the medicine of preparation treatment upper respiratory tract infection, it is characterised in that this compound has having structure:
8. purposes according to claim 7, it is characterised in that described infection is caused by legionella pneumophilia ATCC33152。
9. compound purposes in the medicine of preparation vitro inhibition legionella pneumophilia ATCC33152, it is characterised in that this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610130125.5A CN105687189A (en) | 2016-03-08 | 2016-03-08 | Medicine composition for treating upper respiratory tract infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610130125.5A CN105687189A (en) | 2016-03-08 | 2016-03-08 | Medicine composition for treating upper respiratory tract infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105687189A true CN105687189A (en) | 2016-06-22 |
Family
ID=56220955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610130125.5A Pending CN105687189A (en) | 2016-03-08 | 2016-03-08 | Medicine composition for treating upper respiratory tract infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105687189A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103787976A (en) * | 2014-02-25 | 2014-05-14 | 山东大学 | 1-aryl-3-aryl-1H-pyrromonazole-5-hydroximic acid derivative and application thereof |
| CN104086541A (en) * | 2014-07-18 | 2014-10-08 | 任荣源 | Pharmaceutical composition for treating respiratory tract infections of children |
| CN105085503A (en) * | 2015-09-20 | 2015-11-25 | 徐敬媛 | Medicine composition for treating respiratory tract infection |
-
2016
- 2016-03-08 CN CN201610130125.5A patent/CN105687189A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103787976A (en) * | 2014-02-25 | 2014-05-14 | 山东大学 | 1-aryl-3-aryl-1H-pyrromonazole-5-hydroximic acid derivative and application thereof |
| CN104086541A (en) * | 2014-07-18 | 2014-10-08 | 任荣源 | Pharmaceutical composition for treating respiratory tract infections of children |
| CN105085503A (en) * | 2015-09-20 | 2015-11-25 | 徐敬媛 | Medicine composition for treating respiratory tract infection |
Non-Patent Citations (1)
| Title |
|---|
| JIN-FENG ZHANG,ET AL.: "Biological activities of novel pyrazolyl hydroxamic acid derivatives against human lung cancer cell line A549", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083364B (en) | A kind of pharmaceutical composition for the treatment of the infantile respiratory tract infection that enterobacter cloacae causes | |
| CN105198903B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN104086541B (en) | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection | |
| CN105395538B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN105085503A (en) | Medicine composition for treating respiratory tract infection | |
| CN105687189A (en) | Medicine composition for treating upper respiratory tract infection | |
| CN105232540A (en) | Drug combination for treating infection after burn | |
| CN105412076B (en) | Compound purposes in the medicine of preparation treatment infantile diarrhea | |
| CN105232542B (en) | A kind of pharmaceutical composition for the treatment of infantile pneumonia | |
| CN105348183A (en) | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom | |
| CN105061331A (en) | Pharmaceutical composition for eliminating phlegm for children | |
| CN105294535A (en) | Pharmaceutical composition used for treating pelvic inflammation | |
| CN105237542A (en) | Medicine composition for treating gynecological diseases | |
| CN105777612A (en) | Medicine composition for treating children recurrent respiratory infection | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| CN105748477B (en) | A kind of medicine treating infantile enteritiss | |
| CN105232504A (en) | Medicine composition for treating infant recurrent respiratory tract infections | |
| CN105232550B (en) | A kind of pharmaceutical composition treating chronic pelvic inflammatory disease | |
| CN105769899B (en) | A kind of medicine treating infantile pneumonia | |
| CN105287478B (en) | A kind of pharmaceutical composition treating gastritis | |
| CN105218460A (en) | A kind of pharmaceutical composition for the treatment of enteritis | |
| CN105348270B (en) | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp | |
| CN105796564A (en) | Medicine composition for preventing and treating infection of teeth and dental pulp | |
| CN105125546A (en) | Medicine composition for treating postoperative wound infection | |
| CN105111185A (en) | Pharmaceutical composition for treating vaginitis of elder people |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160622 |
|
| WD01 | Invention patent application deemed withdrawn after publication |